Identification and Evaluation of Circulating Tumor Cells and Tumor Related Rare Cells in Immunotherapy

MiCareo Taiwan Co., Ltd.80 enrolled

Overview

The primary objective of this study is designed to evaluate the enumeration of circulating tumor cells and identify the potential biomarkers associated with clinical outcome. The secondary objective is to explore whether the changes of tumor related rare cells associates clinical outcome.

Study Type

OBSERVATIONAL

Enrollment

Conditions

CTC and Tumor Related Rare Cell

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study. 2. Over 20 years of age. 3. Cancer patients on immune checkpoint inhibitors. Exclusion Criteria: 1. Subjects who have other cancer history 2. Pregnant females 3. Subjects with active, known or suspected autoimmune disease. 4. Known history of human immunodeficiency virus (HIV)

Locations (1)

Taipei Veterans General Hospital

Taipei, Taiwan

RECRUITING

Outcomes

Primary Outcomes

Circulating tumor cell

Isolation and analysis of circulating tumor cells before and after immunotherapy

Time frame: 1 years

Secondary Outcomes

tumor related rare cell

Isolation and analysis of tumor related rare cells before and after immunotherapy

Time frame: 1 years

Central Contacts

Wang Shin-Hang

CONTACT

886-2796-5096 henrywang@micareo.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.